1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow PYC Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 / Phase 2 | Recruiting | PYC Therapeutics | 24 | 2025-09-30 | 2026-06-29 |
| A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration | Phase 1 / Phase 2 | Active not recruiting | PYC Therapeutics | 17 | 2025-06-01 | 2026-05-29 |
Eye Diseases, Hereditary (1) · Optic Atrophies, Hereditary (1) · Optic Atrophy, Autosomal Dominant (1) · Retinal Degeneration (1) · Retinal Diseases (1) · Retinal Dystrophies (1) · Retinitis Pigmentosa 11 (1)
Australia (1) · New Zealand (1) · United States (1)